

Cite Us

Pages: 8 – 14
 Vol. VII, No. II (Spring 2022)
 DOI: 10.31703/gdddr.2022(VII-II).02

p- ISSN: 2788-497X
 e- ISSN: 2788-4120
 URL: http://dx.doi.org/10.31703/gdddr.2022(VII-II).02

Comparing Irritable Bowel Syndrome and Psychiatric Illness to Inflammatory Bowel Disease

Ghaazaan Khan ^a

Ali Ahsan Mufti ^b

Muhammad Kamran Khan ^c

Khalil Azam ^d

Abstract: Irritable bowel syndrome (IBS) is a prevalent disease that patients report within primary care and contributes approximately 14% - 51% of fresh patients to gastrointestinal centres while inflammatory bowel disease (IBD) which includes ulcerative colitis and Crohn's disease, is among the crippling persistent gastrointestinal disorders that considerably negatively affect a participant's physical, psychological, family, and social aspects. The objective of our research was to compare the effects of IBD and IBS in two groups of outpatients. The study was carried out at Qazi Hussain Ahmed Medical Complex Nowshera from September 2021 to Jan 2022. All outpatients with a confirmed diagnosis of IBS (n=49) and IBD (n=27) were requested to participate in the study. 87.76% of patients (n=43) with irritable bowel syndrome and 18.51% of patients (n=5) with inflammatory bowel disease had at least one of these lifetime diagnoses. 24.48%, 22.44%, and 22.44% of the subjects had lifetime diagnoses of major depression (n = 12), panic (n = 11), or somatization disorder (n = 11). 73.5% of the patients with irritable bowel syndrome (n=36) had a history of panic disorder, generalized anxiety disorder, phobia, major depression, somatization disorder, or a combination of these illnesses before the beginning of their gastrointestinal symptoms. Compared to patients with IBD individuals with IBS had greater sensitivity to modest physical symptoms, more psychological discomfort, and a higher lifetime frequency of mental illnesses

Key Words: Inflammatory Bowel Disease, Irritable Bowel Syndrome, Psychiatric Disorders, Anxiety

Introduction

Irritable bowel syndrome (IBS) affects approximately 10% of persons in North America and Europe and is a frequent issue among the overall population (Drossman, D. A., Sandler, R. S., McKee, D. C., & Loviz A. J. <u>1982</u>); Müller-Lissner, S. A., Bollani, S., Brummer, R. J., & Vatn, M. H. et. al. <u>2001</u>). IBS is a prevalent disease that patients report within primary care and contributes approximately 14% - 51% of fresh patients to gastrointestinal centres (Mitchell, C. M., & Drossman, D. A. <u>1987</u>); Thompson, W. G. <u>2000</u>). Health-related quality of life (HRQOL) is greatly affected by functional gastrointestinal disorders and IBS. IBS patients have already been associated with decreasing life quality, as evidenced by impoverished sleep, issues with jobs,

Citation: Khan, G., Mufti, A. A., Khan, M. K., & Azam, K. (2022). Comparing Irritable Bowel Syndrome and Psychiatric Illness to Inflammatory Bowel Disease. *Global Drug Design & Development Review, VII*(II), 8-14. https://doi.org/10.31703/gdddr.2022(VII-II).02

a Assistant Professor, Department of Psychiatry, Jinnah Medical College Peshawar, KP, Pakistan.

^b Associate Professor, Department of Psychiatry, Jinnah Medical College Peshawar, Ibadat Hospital

Peshawar, KP, Pakistan. Email: Aliahsanmuftigmail.com (Corresponding Author)

[°] Assistant Professor, Department of Psychiatry, Qazi Hussain Ahmed Medical Complex, Nowshera, KP, Pakistan.

^d Assistant Professor, Department of Psychiatry, Qazi Hussain Ahmed Medical Complex, Nowshera, KP, Pakistan.

relationship issues, sexual dysfunction, leisure, travel, and nutrition (Koloski, N. A., Talley, N. J., & Boyce, P. M. <u>2000</u>); O Keefe, E. A., Talley, N. J., Zinsmeister, A. R., & Jacobsen, S. J. <u>1995</u>).

Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease, is among the crippling persistent gastrointestinal disorders that considerably negatively affect a participant's physical, psychological, family, and social aspects (Azzam, N., Aljebreen, A., Almuhareb, A., & Almadi, M. 2020). Many IBD participants experienced the psychosocial effects of IBD and its pharmacological therapy. Anxiety especially could have a significant impact on life quality, including workability and family life. (Bannaga, A. S., & Selinger., C. P. 2015). According to population-based studies, IBD patients had cumulative incidence levels of depression and anxiety of 19.8 to 21.7% and 25.3 to 32.6%, correspondingly (Marrie, R. A., Walker, J. R., Graff, L. A., et. al. 2016). According to a previous comprehensive study, individuals with IBD had combined prevalence rates of anxiety and depression of 18.2% and 22.3%, correspondingly (Walus, M. A, Pittet, V., Rossel, J. B., & Von, Kanel. R . 2016).

The medical community and the patient populations have distinct perspectives on these two illnesses, though: Due to the patient's unique personality, psychological makeup, and subjective response to physical or psychological stress, IBS is frequently seen as the archetype of gastrointestinal functional disorders, or an "illness without the disease." Some authors have even gone so far as to call IBS a "forme fruste" of psychiatric illness (Anonymous. 1999); Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. 1976). IBD, on the other hand, is typically seen as "organic," meaning that the disease itself takes precedence over the role that stress or other psychological variables play, which may be little or nonexistent (Powell-Tuck, J., Day, D. W., Buckell, N. A., 1982).

The objective of our research was to compare the effects of IBD and IBS in two groups of outpatients.

Material and Methods

All outpatients with a confirmed diagnosis of IBS were requested to participate in the study between September 2021 to Jan 2022. The majority of the 49 IBS patients who were randomly chosen from the 76 patients in the first sample came from the gastroenterology clinic (n=31; 63.26%) or the private gastroenterologists (n=14; 28.57%); a minor number (n=4; 8.17%) were from the primary care clinic. The 27 first IBD patients showed a similar pattern: primary care clinic (n=6), private practice (n=7), gastroenterology clinic (n=14; 51.86%), and private practice (n=7; 25.92). Within two weeks following their clinic appointment, each patient underwent an evaluation. Patients who had taken oral contraceptives in the month before the interview but not systemic steroids were excluded.

Using the Diagnostic Interview Schedule (DIS) Version Ill-A and III-R criteria, we conducted interviews with the patients after obtaining their consent. These interviews covered somatization disorder, panic disorder, generalized anxiety disorder, phobia, major depressive disorder, and alcoholism sections. In order to determine whether a subject met the requirements for more than one psychiatric diagnosis, we scored the DIS to allow the most valid DSM-III-R psychiatric diagnoses while omitting the exclusion criteria. During the interview, we asked about the current (during the last month) and lifetime symptoms of psychiatric disorders.

All categorical variables, including psychiatric diagnoses and somatic symptoms, were compared between the group with irritable bowel syndrome and the group with inflammatory bowel disease using chi-square testing with Yates' correction and Fisher's exact tests. To find out if the groups varied in the number of symptoms or the results of the psychological tests, two-tailed t-tests were utilized.

Results

Table I summarizes the psychiatric diagnoses. Significantly more patients with irritable bowel syndrome had major depression, somatization disorder, generalized anxiety disorder, panic disorder, and phobic disorder as lifetime diagnoses compared to patients with inflammatory bowel disease; 87.76% of patients (n=43) with irritable bowel syndrome and 18.51% of patients (n=5) with inflammatory bowel disease had at least one of these lifetime diagnoses. In the irritable bowel syndrome group, even after we eliminated generalized anxiety disorder and phobias, 24.48\%, 22.44\%, and 22.44\% of the subjects had lifetime diagnoses of major depression (n = 12), panic (n = 11), or somatization disorder (n = 11).

The patients with Crohn's disease and ulcerative colitis were also compared, and we discovered no significant differences between them in terms of age, sex, marital status, social status, or any psychiatric diagnoses, indicating that they served as a homogenous comparison group for the purposes of this study. We contrasted the age at which gastrointestinal symptoms first appeared with the age at which any mental symptoms that fit the diagnostic mould first appeared. 73.5% of the patients with irritable bowel syndrome (n=36) had a history of panic disorder, generalized anxiety disorder, phobia, major depression, somatization disorder, or a combination of these illnesses before the beginning of their gastrointestinal symptoms (table 2). Thirteen (26.53%) people did not claim to have experienced severe mental symptoms prior to receiving the irritable bowel syndrome diagnosis. Eight of the thirteen individuals experienced a significant depressive illness, panic disorder, or generalized anxiety disorder following the onset of irritable bowel syndrome. Irritable bowel syndrome affected 49 individuals, only five of whom had no prior history of severe mental symptoms either before or after the onset of gastrointestinal symptoms.

Table 3 lists the psychological exam results. Irritable bowel syndrome patients exhibited substantially higher mean scores on seven of the 11 SCL-90 scales and on the Modified Somatic Perception Questionnaire compared to patients with inflammatory bowel illness, but they did not vary on the Beck Depression Inventory.

Diagnoses of disorders	IBS (n=49)		IBD (n=27)		Significance ^a
	n	%	n	%	
Depression					
Life-time	19	(38.77)	5	(18.51)	x²=6.41, p<0.02
Recent	8	(16.32)	2	(7.41)	x ² =2.31
Panic Disorder					
Life-time	II	(22.42)	I	(3.71)	P=0.02
Recent	4	(8.16)	I	(3.71)	P=0.43
Generalized anxiety disorder					
Life-time	14	(28.57)	3	(11.12)	x²=6.13, p<0.05
Recent	2	(4.08)	2	(7.41)	X ² =0.12
Panic or Generalized anxiety disorder					
Life-time	16	(32.65)	4	(14.81)	x²=8.45, p<0.03
Any phobia					
Life-time	16	(32.65)	3	(11.12)	x ² =5.30, p<0.02
Recent	9	(18.36)	2	(7.41)	x ² =1.81
Agoraphobia, life-time	8	(16.32)	Ι	(3.71)	P=0.12
Simple phobia, life-time	9	(18.36)	3	(11.12)	x ² =0.75
Social phobia, life-time	4	(8.16)	2	(7.41)	P=0.22
Somatization disorder, life-time	II	(22.42)	Ι	(3.71)	P=0.04

Table 1. Different Psychiatric disorder analysis of patients with IBS (n=49) and IBD (n=27)

Comparing Irritable Bowel Syndrome and Psychiatric Illness to Inflammatory Bowel Disease

Diagnoses of disorders	IBS (n=49)		IBD (n=27)		Significance ^a	
	n	%	n	%		
Alcohol abuse or dependence, life-time	12	(24.48)	4	(14.81)	x ² =1.32	
Any lifetime analysis	43	(87.76)	5	(22.22)	x²=21.17, p<0.001	
^a Fisher's specific test or the chi-square analysis with Yates' adjustment (df=01).						

Table 2. Psychiatric Signs in patients experiencing IBS (n=49), Predating Gastrointestinal Signs

Patients With Earlier Psychiatric Symptoms Meeting Criteria for Diagnosis						
Disorder Diagnosis	Patient Number	Percentage				
Panic disorder	II	22.44				
General anxiety disorder	29	59.18				
Phobic disorder	17	34.69				
Main depression	12	24.48				
Somatization disorder	II	22.44				
Panic or general anxiety	21	42.85				
Panic or general anxiety or phobia	24	48.97				
Panic or general anxiety or chief depression	21	42.86				
Any of the above detection	36	73.05				

Table 3. Results of psychological self-report questionnaires of IBS and IBD patients (n=49 and 27 respectively).

Survey	IBS		IBD		2 - Tailed t-Test		
	Mean	SD	Mean	SD	t	df	Р
Beck Depression Inventory	8.45	8.6	5.16	7.0	2.49	43	<0.05
Modified Somatic Perception Questionnaire Hopkins SCL-90	9.0	7.0	4.7	6.1	3.05	42	<0.05
Somatization	60.7	10.9	51.2	10.7	1.56	41	<0.05
Obsessive-compulsive	62.2	16.1	54.2	11.6	1.97	41	<0.05
Interpersonal sensitivity	60.8	12.6	52.4	15.4	2.13	41	<0.05
Depression	62.3	12.5	56.7	10.2	1.87	41	<0.05
Anxiety	59.3	14.1	49.5	14.0	2.32	41	<0.05
Hostility	57.4	13.2	48.2	14.5	1.98	41	<0.05
Phobic anxiety	43.4	19.0	41.2	12.9	0.75	41	<0.05
Paranoia	56.4	19.4	44.7	15.9	2.12	41	<0.05
Psychoticism	57.3	19.8	46.7	15.1	2.01	41	<0.05
Global severity	61.5	9.8	$5^{2.7}$	7.9	3.28	41	<0.05
Total Positive symptom	61.7	8.9	55.6	7.2	2.31	41	<0.05

Discussion

According to the findings of this pilot study, people with irritable bowel syndrome had a greater lifetime incidence of mental disorders than patients with other major gastrointestinal diseases. This conclusion is consistent with findings from other studies (Surdea-Blaga, T. <u>2012</u>). We mixed

Crohn's disease and ulcerative colitis patients in order to control for illness severity, and we eliminated people who were on systemic steroids since they have been linked to organic mental symptoms. In the sample with IBS, we discovered a startlingly high frequency of psychiatric problems (87.76%). Despite being comparable to rates discovered in other research (Fadgyas-Stanculete, M., Buga, A. M., (2014). The DSM-III-R criteria we used to calculate the maximum number of diagnoses permitted by the DIS revealed that generalized anxiety disorder (59.18%) affected more than half of our individuals. Irritable bowel syndrome and anxiety tend to be mutually reinforcing rather than that one illness directly causes the other, however, the causal link between the two disorders is poorly understood (Palsson, O. S., & Drossman, D. A. 2005). Major depression (24.48%), panic (22.44%), and somatization disorder (22.44%) were the three most common lifetime psychiatric diagnoses for patients, even after excluding generalized anxiety disorder and phobias related to irritable bowel syndrome. Despite being roughly identical to rates discovered in other research (Mykletun, A., Jacka, F., et. al. 2010). Furthermore, the majority (73.05%) of our IBS patients said that the commencement of their psychological symptoms came on before the onset of their gastrointestinal distress.

The SCL-90 revealed that the individuals with irritable bowel syndrome also had a significant level of present psychological distress, despite differences between our two groups of respondents in lifetime psychiatric diagnoses. These findings imply that many IBS patients also suffer from anxiety and depression and that even between acute episodes, they continue to experience significant yet subclinical psychological suffering. In several research, it has been discovered that patients with high levels of psychological distress or "negative affectivity" (those with high anxiety, despair, and hostility scores on psychological measures of distress) report noticeably more physical symptoms than healthy participants (Locke III, R. G., Zinsmeister, A. R., Schleck, C. D., & Talley, N. J. 2009). According to our research, people with irritable bowel syndrome may exaggerate little physiological symptoms. The Modified Somatic Perception Questionnaire, the SCL-90, and our data from the DIS's section on somatization disorders all show that patients with irritable bowel syndrome reported more mild somatic symptoms than patients with inflammatory bowel disease.

Conclusion

Overall, compared to patients with inflammatory bowel disease, individuals with irritable bowel syndrome had greater sensitivity to modest physical symptoms, more psychological discomfort, and a higher lifetime frequency of mental illnesses. These results imply that these individuals may benefit from formal psychiatric assessment and treatment using both psychotherapy and psychopharmacologic techniques.

References

- Anonymous. (1999). Illness without the disease. *Harvard Mental Health Letter, 16*, 1–4.
- Azzam, N., Aljebreen, A., Almuhareb, A., & Almadi, M. (2020). Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients. Saudi Journal of Gastroenterology, 26(5), 256. https://doi.org/10.4103/sjg.sjg 175 20
- Bannaga, A. S., & Selinger., C. P. (2015).
 Inflammatory bowel disease and anxiety: links, risks, and challenges faced. *Clinical and Experimental Gastroenterology*, 111. <u>https://doi.org/10.2147/ceg.s57982</u>
- Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976). Development of a Crohns Disease Activity Index. *Gastroenterology*, 70(3), 439–444. <u>https://doi.org/10.1016/s0016-5085(76)80163-1</u>
- Drossman, D. A., Sandler, R. S., McKee, D. C., & Loviz A. J. (1982). Bowel patterns among subjects not seeking health care. *Gastroenterology* 83(3), 29–34. https://pubmed.ncbi.nlm.nih.gov/7095360/
- Fadgyas-Stanculete, M., Buga, A. M., Popa-Wagner, A., & Dumitrascu, D. L. (2014). The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations. *Journal of Molecular Psychiatry*, 2(1). https://doi.org/10.1186/2049-9256-2-4
- Koloski, N. A., Talley, N. J., & Boyce, P. M. (2000). The impact of functional gastrointestinal disorders on quality of life. *The American Journal of Gastroenterology*, *95*(1), 67–71. <u>https://doi.org/10.1111/j.1572-0241.2000.01735.x</u>
- Locke III, R. G., Zinsmeister, A. R., Schleck, C. D., & Talley, N. J. (2009). Psychosocial

Distress and Somatic Symptoms in Community Subjects With Irritable Bowel Syndrome: A Psychological Component Is the Rule. *The American Journal of Gastroenterology*, *104*(7), 1772– 1779. https://doi.org/10.1038/ajg.2009.239

- Marrie, R. A., Walker, J. R., Graff, L. A., Lix, L. M., Bolton, J. M., Nugent, Z., Targownik, L. E., & Bernstein, C. N. (2016). Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease. *Journal of Psychosomatic Research*, *89*, 107–113. https://doi.org/10.1016/j.jpsychores.2016.08. 014
- Mitchell, C. M., & Drossman, D. A. (1987).
 Survey of the AGA Membership Relating to Patients With Functional Gastrointestinal Disorders. *Gastroenterology*, *92*(5), 1282– 1284. <u>https://doi.org/10.1016/s0016-5085(87)91099-7</u>
- Müller-Lissner, S. A., Bollani, S., Brummer, R. J., Coremans, G., Dapoigny, M., Marshall, J. K., Muris, J. W., Oberndorff-Klein Wolthuis, A., Pace, F., Rodrigo, L., Stockbrügger, R., & Vatn, M. H. (2001). Epidemiological Aspects of Irritable Bowel Syndrome in Europe and North America. *Digestion*, *64*(3), 200–204. https://doi.org/10.1159/000048862
- Mykletun, A., Jacka, F., Williams, L., Pasco, J., Henry, M., Nicholson, G. C., ... & Berk, M. (2010). Prevalence of mood and anxiety disorder in self-reported irritable bowel syndrome (IBS). An epidemiological population-based study of women. *BMC* gastroenterology, 10(1), 1-9. https://doi.org/10.1186/1471-230X-10-88
- OKeefe, E. A., Talley, N. J., Zinsmeister, A. R., & Jacobsen, S. J. (1995). Bowel Disorders Impair Functional Status and Quality of Life in the Elderly: A Population-Based Study.

The Journals of Gerontology Series A:Biological Sciences and Medical Sciences,50A(4),https://doi.org/10.1093/gerona/50a.4.m184

- Palsson, O. S., & Drossman, D. A. (2005). Psychiatric and Psychological Dysfunction in Irritable Bowel Syndrome and the Role of Psychological Treatments. *Gastroenterology Clinics of North America*, 34(2), 281–303. https://doi.org/10.1016/j.gtc.2005.02.004
- Powell-Tuck, J., Day, D. W., Buckell, N. A., Wadsworth, J., & Lennard-Jones, J. E. (1982). Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. *Digestive Diseases and Sciences*, 27(6), 533–537. https://doi.org/10.1007/bfo1296733
- Surdea-Blaga, T. (2012). Psychosocial determinants of irritable bowel syndrome. World Journal of Gastroenterology, 18(7), 616. <u>https://doi.org/10.3748/wjg.v18.i7.616</u>

- Thompson, W. G. (2000). Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. *Gut*, 46(1), 78–82. <u>https://doi.org/10.1136/gut.46.1.78</u>
- Walker, E. A., Roy-Byrne, P. P., & Katon, W. J. (1990). Irritable bowel syndrome and psychiatric illness. *American Journal of Psychiatry*, 147(5), 565–572. https://doi.org/10.1176/ajp.147.5.565
- Walus, M. A, Pittet, V., Rossel, J. B., & Von, Kanel. R .(2016). Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. *Clinical Gastroenterology* and *Hepatology*, 14(6), 829-835.e1. https://doi.org/10.1016/j.cgh.2015.12 .045
- Whitehead, W. E., Burnett, C. K., Cook, E. W., & Taub, E. (1996). Impact of irritable bowel syndrome on quality of life. *Digestive Diseases and Sciences*, 41(11), 2248–2253. <u>https://doi.org/10.1007/bf02071408</u>